Workshop

European Molecular Biology Organization

 

Tumour suppressors

 

 

 

 

 



10-11 May | 2010 | L'Hospitalet de Llobregat (Barcelona) | Spain

Programme


Monday 10th May

09:00

Welcome Address

Sr Emilià Pola, IDIBELL, General Director

Manel Esteller, MD, PhD. PEBC Director

Session I: ANIMAL MODELS FOR TUMOR SUPPRESSORS

Chair: David Sidransky 

09:15

Anton Berns

Conditional tumor suppressor knockout mouse models for lung cancer and mesothelioma

09:50

Suzanne Baker

Tumor Suppressor Pathways in Gliomagenesis

10:25

Short talk

Jose Yelamos

Functional interplay between Poly(ADP-ribose) polymerase-2 and p53 in tumour suppression

10:40

Short talk

Jesus Paramio

Epithelial-mesenchymal transition and metastasis associated with deregulated miRNA expression in Trp53-deficient squamous cell carcinoma

10:55

Coffee break and poster session

11:30

Elisabeth P Henske

Cancer mutations and targeted therapies in cells, mice and patients

12:05

Manuel Serrano

Tumor Suppressors beyond Cancer: role in Aging and Metabolism

12:40

Short talk

Maria L Martinez-Chantar

Activation of LKB1-Akt pathway independent of PI3 Kinase plays a critical role in the development of hepatocellular carcinoma from NASH

12:55

Lunch and poster session I

Session II: FAMILIAL CANCER

Chair: Elisabeth P. Henske

14:30

Javier Benitez

Familial breast cancer. Where are we and where do we go

15:05

Conxi Lazaro

Neurofibromatosis type 1: From mutation analysis to antisense therapeutics

15:40

Eric Legius

The Ras-o-pathies: inherited disorders of the RAS-pathway

16:15

Coffee break and poster session

16:45

Jordi Surralles

Fanconi anemia: a paradigm of cancer prone syndrome

17:20

Short talk

Miquel Angel Pujana

A molecular mechanism for mammary epithelial differentiation linked to BRCA1 and risk of breast cancer

17:45

Short talk

Laura Valle

Blood telomere length and variation in telomere-related genes in hereditary and sporadic colorectal cancer patients

Tuesday 11th May

Session III: FAMILIAL CANCER: NOVEL THERAPIES AND CLINICAL MANAGEMENT

Chair: Anton Berns

9:30   

Lauri Aaltonen

Prevention of malignancy in hereditary nonpolyposis colorectal cancer; the Finnish experience

10:05

Ian Tomlinson

Tumour suppressor genes: still a useful concept?

10:40

Short talk

Hans-Guido Wendel

EphA receptor signaling – a new, soluble tumor suppressor pathway in lymphoma

10:55

Group Picture - Coffee break and poster session

12:00

Alan Ashworth

Synthetic Lethal Approaches to Cancer Therapy

12:35

Short talk

Jean Imbert

The potential tumor suppressor GATA4 directly represses ERBB2 expression - Nuclear expression mechanism for the ERBB2 receptor and role in breast cancer cells

12:50

Short talk

Kucharczyk Krzysztof

MSSCP genotyping method for a fast and cost effective detection of 1% of minor KRAS genetic variants in heterogenic clinical material

13:05

Lunch and poster session

Session IV: NOVEL TUMOR SUPPRESSORS

Chair: Alan Ashworth

14:30

David Sidransky

Integrating molecular markers and tumorgrafts to personalize cancer therapy

15:05

Alberto Bardelli

Cancer mutations and targeted therapies in cells, mice and patients

15:40

Short talk

Pedro Lazo

Double autoregulatory loop between VRK1-p53 and DRAM in response to genotoxic damage

15:55

Coffee break and poster session

16:30

Andre Futreal

Somatic genetics of human cancer: moving towards large scale sequencing of cancer genomes

17:05

Montse Sanchez-Cespedes

Identification of novel tumor suppressor genes in lung cancer

17:40

Short talk

Hugo Prazeres

Chromosomal, epigenetic and microRNA-mediated changes leading to LRP1B inactivation and modulation of the tumor microenvironment

Closing remarks

European Molecular Biology Organization | Meyerhofstrasse 1 | 69117 Heidelberg | Germany